Program
Naproxen
Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.
Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.
Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 240 open or running | phase 4since Apr 15, 2010 | Jun 5, 2008 | none ahead |
| Pfizerits history only | 80 open or running | phase 4since Mar 28, 2008 | Aug 17, 2006 | none ahead |
| GlaxoSmithKlineits history only | 70 open or running | phase 4since Nov 17, 2008 | Oct 14, 2005 | none ahead |
| Aralez Pharmaceuticalsits history only | 60 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Merckits history only | 40 open or running | phase 4since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 20 open or running | phase 3since Jul 7, 2011 | Jul 7, 2011 | none ahead |
| Perrigoits history only | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Analgesic Solutionsits history only | 10 open or running | no phasesince Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Kenvue Brandsits history only | 11 open or running | phase 3since Oct 15, 2026 | Oct 15, 2026 | Oct 29, 2027phase 3 · NCT07948811 |
Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bayer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jun 5, 2008.
- Jul 6, 2011Phase 3 study in Pain, PostoperativeNCT01389284 · 300 enrolled · United States
- Aug 31, 2011Phase 3 study in PainNCT01427803 · 778 enrolled · United States
- Dec 16, 2011Phase 3 study in Pain, PostoperativeNCT01495858 · 267 enrolled · United States
- Jul 31, 2014Phase 1 study in HematologyNCT02229461 · 117 enrolled · United States
- Aug 17, 2015Phase 1 study in PainNCT02549469 · 32 enrolled
- Jan 12, 2018Phase 4 study in Pain, PostoperativeNCT03404206 · 387 enrolled · United States
- Feb 9, 2018Phase 4 study in DysmenorrheaNCT03448536 · 201 enrolled · United States
- Jun 18, 2018Phase 2 study in Osteoarthritis, KneeNCT03570554 · 41 enrolled · United States
- Oct 8, 2019Phase 2 study in Pain, PostoperativeNCT04132336 · 193 enrolled · United States
- Mar 5, 2020Phase 4 study in PainNCT04307940 · 221 enrolled · United States
- Jul 12, 2021Phase 2 study in Soft Tissue InjuriesNCT05026320 · 76 enrolled · Germany
- Jul 28, 2022Phase 3 study in ToothacheNCT05485805 · 541 enrolled · United States
- May 10, 2024Phase 1 study in PainNCT06415019 · 236 enrolled · United States
- Jul 11, 2024Phase 1 study in PainNCT06511973 · 42 enrolled · United States
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 137 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 24 Bayer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06511973Pain · United States | 1 | Completed | Aug 20, 2024 | 42 |
| NCT06415019Pain · United States | 1 | Completed | Aug 1, 2024 | 236 |
| NCT05485805Toothache · United States | 3 | Completed | Jan 25, 2024 | 541 |
| NCT05026320Soft Tissue Injuries · Germany | 2 | Completed | Dec 20, 2021 | 76 |
| NCT04307940Pain · United States | 4 | Completed | Oct 2, 2020 | 221 |
| NCT04132336Pain, Postoperative · United States | 2 | Completed | Mar 2, 2020 | 193 |
| NCT03570554Osteoarthritis, Knee · United States | 2 | Completed | Jun 14, 2019 | 41 |
| NCT03448536Dysmenorrhea · United States | 4 | Completed | Sep 5, 2018 | 201 |
| NCT03404206Pain, Postoperative · United States | 4 | Completed | Jul 6, 2018 | 387 |
| NCT02549469Pain | 1 | Completed | May 2007 | 32 |
| NCT02229461Hematology · United States | 1 | Completed | May 2015 | 117 |
| NCT01495858Pain, Postoperative · United States | 3 | Completed | Feb 2012 | 267 |
| NCT01427803Pain · United States | 3 | Completed | Dec 2011 | 778 |
| NCT01389284Pain, Postoperative · United States | 3 | Completed | Sep 2011 | 300 |
| NCT01383486Pain · United States | 3 | Completed | Aug 2011 | 253 |
| NCT01365052Pain · United States | 3 | Completed | Jul 2011 | 326 |
| NCT01280591Pain, Postoperative · United States | 3 | Completed | Jan 2011 | 712 |
| NCT01118273Sleep · United States | 4 | Completed | Feb 2008 | 162 |
| NCT00969449Pharmacokinetics · United States | 1 | Completed | May 2009 | 28 |
| NCT00818415Pain · United States | 1 | Completed | Nov 2008 | 32 |
| NCT00751556Healthy · United States | 1 | Completed | Mar 2008 | 32 |
| NCT00751400Pain · United States | 3 | Completed | Nov 2008 | 497 |
| NCT00720057Toothache · United States | 3 | Completed | Aug 2008 | 312 |
| NCT00692016Bioavailability · United States | 1 | Completed | Feb 2008 | 32 |
How it is read
Names in the registry
- “Naproxen”, 17 entries
- “PN400”, 8 entries
- “naproxen”, 5 entries
- “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
- “Naproxen Sodium ER (BAYH6689)”, 4 entries
Conditions, from the studies’ own filings
- Pain, 12 studies
- Osteoarthritis, 9 studies
- Migraine Disorders, 8 studies
- Osteoarthritis, Knee, 5 studies
- Pain, Postoperative, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.